Skip to content

Study · Non-randomized trial · n = 15 · 1994

9 results

Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome.

Leal-Cerro A, Pumar A, Garcia-Garcia E, Dieguez C, Casanueva FF

Clinical endocrinology1 Nov 1994Cited by 29 (Europe PMC)

PMID7828354 (opens in a new tab)DOI10.1111/j.1365-2265.1994.tb01831.x (opens in a new tab)PepBankPUB-07828354
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    Patients with Cushing's syndrome showed lower GH secretion after GHRP‑6 than healthy controls.

    In plain wordsPatients with Cushing's syndrome released less growth hormone after GHRP‑6 than healthy controls.

    Peptide
    GHRP-6
    Outcome
    DecreaseGH AUC versus healthy controls
    Study

    n = 15

    Comparator
    Healthy controls given GHRP-6
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms · intravenousAs given in this study (human).

    Measurements

    GH AUC
    530 mU/I/120 min
    Cushing's syndrome after GHRP-6
    GH AUC
    2278 mU/I/120 min
    Healthy controls after GHRP-6

    Source sentences

    Summary
    The areas under the curve (AUC) of GH secretion (mean +/- SEM in mU/I/120 min) in the control subjects after each test were: GHRH, 1420 +/- 330; GHRP-6, 2278 +/- 290 and GHRH plus GHRP-6, 7332 +/- 592 (P < 0.05 vs each compound alone). The AUCs for Cushing's syndrome patients were: GHRH, 248 +/- 165…
    3 context sentences
    Summary · context
    Three different tests were undertaken: (a) GHRH 100 micrograms i.v.; (b) GHRP-6 100 micrograms i.v. and (c) GHRH plus GHRP-6 100 micrograms i.v. of each; administered to each subject on different days, at least 4 days apart.
    Summary · context
    Ten patients (8 women, 2 men) with untreated Cushing's syndrome, 9 Cushing's disease and 1 adrenal adenoma.
    Summary · context
    Five healthy volunteers (3 women, 2 men) of similar ages served as a control group.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with Cushing's syndrome, GHRP‑6 produced a GH AUC of 530 mU/I/120 min.

    In plain wordsIn patients with Cushing's syndrome, GHRP‑6 produced a growth hormone AUC of 530 mU/I/120 min.

    Peptide
    GHRP-6
    Outcome
    Not applicableGH AUC in Cushing's syndrome
    Study

    n = 10

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms · intravenousAs given in this study (human).

    Measurements

    GH AUC
    530 mU/I/120 min
    Cushing's syndrome after GHRP-6

    Source sentences

    Summary
    The AUCs for Cushing's syndrome patients were: GHRH, 248 +/- 165; GHRP-6 530 +/- 170 and for GHRH plus GHRP-6, 870 +/- 258 (P < 0.05 vs GHRH alone).
    4 context sentences
    Summary · context
    The areas under the curve (AUC) of GH secretion (mean +/- SEM in mU/I/120 min) in the control subjects after each test were:
    Summary · context
    Three different tests were undertaken: (a) GHRH 100 micrograms i.v.; (b) GHRP-6 100 micrograms i.v. and (c) GHRH plus GHRP-6 100 micrograms i.v. of each; administered to each subject on different days, at least 4 days apart.
    Summary · context
    Ten patients (8 women, 2 men) with untreated Cushing's syndrome, 9 Cushing's disease and 1 adrenal adenoma.
    Summary · context
    Five healthy volunteers (3 women, 2 men) of similar ages served as a control group.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with Cushing's syndrome, adding GHRP‑6 to GHRH significantly increased GH secretion compared with GHRH alone.

    In plain wordsIn patients with Cushing's syndrome, adding GHRP‑6 to GHRH released more growth hormone than GHRH alone.

    Peptide
    GHRP-6
    Outcome
    IncreaseCombination GH AUC versus GHRH in Cushing's syndrome
    Study

    n = 10

    Comparator
    GHRH alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms · intravenousAs given in this study (human).

    Measurements

    GH AUC
    870 mU/I/120 min
    Cushing's syndrome after GHRH plus GHRP-6
    GH AUC
    248 mU/I/120 min
    Cushing's syndrome after GHRH alone

    Source sentences

    Summary
    The AUCs for Cushing's syndrome patients were: GHRH, 248 +/- 165; GHRP-6 530 +/- 170 and for GHRH plus GHRP-6, 870 +/- 258 (P < 0.05 vs GHRH alone).
    4 context sentences
    Summary · context
    The areas under the curve (AUC) of GH secretion (mean +/- SEM in mU/I/120 min) in the control subjects after each test were:
    Summary · context
    Three different tests were undertaken: (a) GHRH 100 micrograms i.v.; (b) GHRP-6 100 micrograms i.v. and (c) GHRH plus GHRP-6 100 micrograms i.v. of each; administered to each subject on different days, at least 4 days apart.
    Summary · context
    Ten patients (8 women, 2 men) with untreated Cushing's syndrome, 9 Cushing's disease and 1 adrenal adenoma.
    Summary · context
    Five healthy volunteers (3 women, 2 men) of similar ages served as a control group.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy controls, GHRP‑6 produced a GH AUC of 2278 mU/I/120 min.

    In plain wordsIn healthy controls, GHRP‑6 produced a growth hormone AUC of 2278 mU/I/120 min.

    Peptide
    GHRP-6
    Outcome
    Not applicableGH AUC in healthy controls
    Study

    n = 5

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms · intravenousAs given in this study (human).

    Measurements

    GH AUC
    2278 mU/I/120 min
    Healthy controls after GHRP-6

    Source sentences

    Summary
    The areas under the curve (AUC) of GH secretion (mean +/- SEM in mU/I/120 min) in the control subjects after each test were: GHRH, 1420 +/- 330; GHRP-6, 2278 +/- 290 and GHRH plus GHRP-6, 7332 +/- 592 (P < 0.05 vs each compound alone).
    3 context sentences
    Summary · context
    Three different tests were undertaken: (a) GHRH 100 micrograms i.v.; (b) GHRP-6 100 micrograms i.v. and (c) GHRH plus GHRP-6 100 micrograms i.v. of each; administered to each subject on different days, at least 4 days apart.
    Summary · context
    Ten patients (8 women, 2 men) with untreated Cushing's syndrome, 9 Cushing's disease and 1 adrenal adenoma.
    Summary · context
    Five healthy volunteers (3 women, 2 men) of similar ages served as a control group.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy controls, adding GHRP‑6 to GHRH significantly increased GH secretion compared with GHRH alone.

    In plain wordsIn healthy controls, adding GHRP‑6 to GHRH released more growth hormone than GHRH alone.

    Peptide
    GHRP-6
    Outcome
    IncreaseCombination GH AUC versus GHRH in controls
    Study

    n = 5

    Comparator
    GHRH alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms · intravenousAs given in this study (human).

    Measurements

    GH AUC
    7332 mU/I/120 min
    Healthy controls after GHRH plus GHRP-6
    GH AUC
    1420 mU/I/120 min
    Healthy controls after GHRH alone

    Source sentences

    Summary
    The areas under the curve (AUC) of GH secretion (mean +/- SEM in mU/I/120 min) in the control subjects after each test were: GHRH, 1420 +/- 330; GHRP-6, 2278 +/- 290 and GHRH plus GHRP-6, 7332 +/- 592 (P < 0.05 vs each compound alone).
    3 context sentences
    Summary · context
    Three different tests were undertaken: (a) GHRH 100 micrograms i.v.; (b) GHRP-6 100 micrograms i.v. and (c) GHRH plus GHRP-6 100 micrograms i.v. of each; administered to each subject on different days, at least 4 days apart.
    Summary · context
    Ten patients (8 women, 2 men) with untreated Cushing's syndrome, 9 Cushing's disease and 1 adrenal adenoma.
    Summary · context
    Five healthy volunteers (3 women, 2 men) of similar ages served as a control group.

Studies that did not test the peptide alone4

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 06HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    Patients with Cushing's syndrome showed lower GH secretion after GHRH plus GHRP‑6 than healthy controls.

    In plain wordsPatients with Cushing's syndrome released less growth hormone after GHRH plus GHRP‑6 than healthy controls.

    Peptide
    GHRP-6
    Outcome
    DecreaseCombination GH AUC versus healthy controls
    Study

    n = 15

    Comparator
    Healthy controls given GHRH plus GHRP-6
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH AUC
    870 mU/I/120 min
    Cushing's syndrome after GHRH plus GHRP-6
    GH AUC
    7332 mU/I/120 min
    Healthy controls after GHRH plus GHRP-6

    Source sentences

    Summary
    The areas under the curve (AUC) of GH secretion (mean +/- SEM in mU/I/120 min) in the control subjects after each test were: GHRH, 1420 +/- 330; GHRP-6, 2278 +/- 290 and GHRH plus GHRP-6, 7332 +/- 592 (P < 0.05 vs each compound alone). The AUCs for Cushing's syndrome patients were: GHRH, 248 +/- 165…
    3 context sentences
    Summary · context
    Three different tests were undertaken: (a) GHRH 100 micrograms i.v.; (b) GHRP-6 100 micrograms i.v. and (c) GHRH plus GHRP-6 100 micrograms i.v. of each; administered to each subject on different days, at least 4 days apart.
    Summary · context
    Ten patients (8 women, 2 men) with untreated Cushing's syndrome, 9 Cushing's disease and 1 adrenal adenoma.
    Summary · context
    Five healthy volunteers (3 women, 2 men) of similar ages served as a control group.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 07HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    After GHRH plus GHRP‑6, only one of ten patients with hypercortisolism had a GH peak above 20 mU/I.

    In plain wordsAfter GHRH plus GHRP‑6, only one of ten patients with hypercortisolism had a growth hormone peak above 20 mU/I.

    Peptide
    GHRP-6
    Outcome
    Not applicableGH peak responder proportion
    Study

    n = 10

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Responders
    1 patients
    GH peak over 20 mU/I among ten patients

    Source sentences

    Summary
    After the combined stimulus only one out of the ten patients with hypercortisolism showed a GH peak over 20 mU/I, while all the controls had a peak over 84 mU/I.
    3 context sentences
    Summary · context
    Three different tests were undertaken: (a) GHRH 100 micrograms i.v.; (b) GHRP-6 100 micrograms i.v. and (c) GHRH plus GHRP-6 100 micrograms i.v. of each; administered to each subject on different days, at least 4 days apart.
    Summary · context
    Ten patients (8 women, 2 men) with untreated Cushing's syndrome, 9 Cushing's disease and 1 adrenal adenoma.
    Summary · context
    Five healthy volunteers (3 women, 2 men) of similar ages served as a control group.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 08HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In healthy controls, GHRH plus GHRP‑6 produced significantly greater GH secretion than GHRP‑6 alone.

    In plain wordsIn healthy controls, GHRH plus GHRP‑6 released more growth hormone than GHRP‑6 alone.

    Peptide
    GHRP-6
    Outcome
    IncreaseCombination GH AUC versus GHRP-6 in controls
    Study

    n = 5

    Comparator
    GHRP-6 alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH AUC
    7332 mU/I/120 min
    Healthy controls after GHRH plus GHRP-6
    GH AUC
    2278 mU/I/120 min
    Healthy controls after GHRP-6 alone

    Source sentences

    Summary
    The areas under the curve (AUC) of GH secretion (mean +/- SEM in mU/I/120 min) in the control subjects after each test were: GHRH, 1420 +/- 330; GHRP-6, 2278 +/- 290 and GHRH plus GHRP-6, 7332 +/- 592 (P < 0.05 vs each compound alone).
    3 context sentences
    Summary · context
    Three different tests were undertaken: (a) GHRH 100 micrograms i.v.; (b) GHRP-6 100 micrograms i.v. and (c) GHRH plus GHRP-6 100 micrograms i.v. of each; administered to each subject on different days, at least 4 days apart.
    Summary · context
    Ten patients (8 women, 2 men) with untreated Cushing's syndrome, 9 Cushing's disease and 1 adrenal adenoma.
    Summary · context
    Five healthy volunteers (3 women, 2 men) of similar ages served as a control group.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 09HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    After GHRH plus GHRP‑6, all five healthy controls had a GH peak above 84 mU/I.

    In plain wordsAfter GHRH plus GHRP‑6, all five healthy controls had a growth hormone peak above 84 mU/I.

    Peptide
    GHRP-6
    Outcome
    Not applicableGH peak responder proportion in healthy controls
    Study

    n = 5

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    After the combined stimulus only one out of the ten patients with hypercortisolism showed a GH peak over 20 mU/I, while all the controls had a peak over 84 mU/I.
    2 context sentences
    Summary · context
    Five healthy volunteers (3 women, 2 men) of similar ages served as a control group.
    Summary · context
    Three different tests were undertaken: (a) GHRH 100 micrograms i.v.; (b) GHRP-6 100 micrograms i.v. and (c) GHRH plus GHRP-6 100 micrograms i.v. of each; administered to each subject on different days, at least 4 days apart.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.